SEGULAH IV L.P. DIVESTS CCS HEALTHCARE On March 1, 2019, Segulah IV L.P. and minority shareholders signed an agreement to divest 100% of CCS Healthcare Holding AB to KiiltoClean Group. KiiltoClean Group is a part of Kiilto, a family-owned Finnish company that develops, manufactures and markets chemical industry solutions and operates in four business areas: construction, industrial bonding and hygiene solutions, professional cleanliness and hygiene and consumer products. The transaction was simultaneously carried through. CCS Healthcare provides hygiene and safety products to the professional business-to-business markets and holds the leading position within hand hygiene and surface disinfection products in the Nordic region. Additionally, the Company holds a strong position within portable eyewash products in Denmark and Germany. CCS Healthcare was acquired by Segulah IV in May 2011. During Segulah IVs ownership, CCS Healthcare has completed four add-on acquisitions, mainly within the hygiene product segment. In March 2016, CCS Healthcare divested its pharma portfolio and Clinomyn brand to Trimb Healthcare. The Consumer Skincare business unit was divested through two sepa- rate transactions in January 2019. The skincare brand portfolio was acquired by Trimb Healthcare and the factory and contract manufacturing activities in Sweden were acquired by Svenska Krämfabriken. Pro forma for the Consumer Skincare divestment, CCS Healthcare generated revenues of ca. MSEK 440 in 2018. "CCS Healthcare has in recent years significantly transformed its operations and showed good profitable growth. Following the successful divestment of the Consumer Skincare business unit, the industrial merit of combining CCS Healthcare with Kiilto is evident, creating a Nordic powerhouse positioned for future growth", says Dario Aganovic, CEO of CCS Healthcare. "We are very pleased with how CCS Healthcare has performed over the past years under the leadership of the current management team. We are convinced that Kiilto as a new owner will be able to further develop CCS Healthcares strong position across key Nordic and European markets", says Sebastian Ehrnrooth, Chairman of Segulah Advisor AB. Stockholm, March 1, 2019 For further information, please visit www.segulah.com http://www.segulah.com or contact: Dario Aganovic, CEO, CCS Healthcare, +46 72 555 11 01 Sebastian Ehrnrooth, Chairman, Segulah Advisor AB, +46 73 360 42 05 Johan Möllerström, Director, Segulah Advisor AB, +46 72 543 79 11 The following documents can be retrieved from beQuoted Segulah Pressrelease 2019-03-01 English.pdf-http://www.bequoted.com/beQPress/download.asp?Id=25372 Founded in 1994, Segulah is a private equity partnership focused on mid-market buyouts in the Nordic region, with a business model of active ownership through its extensive network of industrial advisors. Segulah Advisor AB is the exclu- sive investment advisor to the UK Limited Partnerships Segulah III L.P., Segulah IV L.P. and Segulah V L.P.